Back to Results

A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)

Study category: Kidney Disease & Hypertension

Is this Study for You?

Let's Get Started!

Description

A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)

Details
Age

Child to Adult

Eligibility

-confirmed diagnosis of C3G by review of renal biopsy no more than 30 das of first dose of study drug -ages 18-65 -no prior treatment with ACH-0144471

Phase

II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Type of Study

Treatment

Locations

Childrens Hospital Colorado
University of Colorado Hospital

Principal Investigator
Bradley Dixon

Bradley Dixon

Study ID

Protocol Number: 17-2178

ClinicalTrials.gov: NCT03369236

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers